MedPath

Atox Bio Ltd.

Atox Bio Ltd. logo
🇮🇱Israel
Ownership
Private
Established
2003-01-01
Employees
1
Market Cap
-
Website
http://www.atoxbio.com

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

Phase 3
Terminated
Conditions
Necrotizing Soft Tissue Infection
Peritonitis
Acute Kidney Injury
Interventions
First Posted Date
2018-01-19
Last Posted Date
2021-10-12
Lead Sponsor
Atox Bio Ltd
Target Recruit Count
58
Registration Number
NCT03403751
Locations
🇺🇸

Maricopa Medical Center, Phoenix, Arizona, United States

🇺🇸

Banner University Medical Center, Tucson, Arizona, United States

🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 53 locations

Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections

Phase 3
Completed
Conditions
Fournier's Gangrene
Necrotizing Fasciitis
Necrotizing Soft Tissue Infections
Interventions
Drug: AB103 0.5 mg/kg
Other: NaCl 0.9%
First Posted Date
2015-06-12
Last Posted Date
2021-10-05
Lead Sponsor
Atox Bio Ltd
Target Recruit Count
290
Registration Number
NCT02469857
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Maricopa Medical Center, Phoenix, Arizona, United States

🇺🇸

Banner University Medical Center, Tucson, Arizona, United States

and more 68 locations

Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients

Phase 2
Completed
Conditions
Necrotizing Soft Tissue Infections
Interventions
Drug: Placebo
First Posted Date
2011-08-16
Last Posted Date
2021-08-18
Lead Sponsor
Atox Bio Ltd
Target Recruit Count
43
Registration Number
NCT01417780
Locations
🇺🇸

University of Southern California Los Angeles, Los Angeles, California, United States

🇺🇸

San Francisco General Hospital, San Francisco, California, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

and more 4 locations

AB103 Peptide Antagonist in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer Safety Study
Interventions
Drug: Placebo
First Posted Date
2010-07-21
Last Posted Date
2021-06-09
Lead Sponsor
Atox Bio Ltd
Target Recruit Count
25
Registration Number
NCT01166984
Locations
🇺🇸

University of Maryland School of Medicine, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath